Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01707043 · ClinicalTrials.gov registry record · Phase 4
Patient Preference of Taclonex Ointment to Taclonex Scalp Suspension in Adult Subjects With Psoriasis Vulgaris
A Phase 4 study of Plaque Psoriasis, sponsored by Wake Forest University.
- Completed
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT01707043 is a Phase 4 study of Plaque Psoriasis that has completed, run by Wake Forest University. The registered enrollment target is 20 participants, below the 415-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01707043, a Phase 4 study of Plaque Psoriasis, has completed, sponsored by Wake Forest University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open label, investigator-blinded, cross over, prospective, single center study of subjects with plaque psoriasis. Taclonex® (calcipotriene 0.005% and betamethasone dipropionate 0.064%) Ointment and Taclonex Scalp® (calcipotriene 0.005% and betamethasone dipropionate 0.064%) Topical Suspension will each be applied topically once daily. The primary objective is to assess the patient preference for Taclonex® (calcipotriene 0.005% and betamethasone dipropionate 0.064%) Ointment compared to Taclonex Scalp® (calcipotriene 0.005% and betamethasone dipropionate 0.064%) Topical Suspension in the treatment of plaque psoriasis.
Conditions Studied
Interventions
- DRUG Taclonex
Study Locations (1)
North Carolina
- Wake Forest University Health Sciences - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2012-10 |
| Est. Completion | 2013-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01707043
The ClinicalTrials.gov registry entry for NCT01707043 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 415-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (95% lower). The listed sponsor is Wake Forest University, which has 100 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Plaque Psoriasis appearing as the primary indexed condition, and to 1 intervention - of which Taclonex is the first listed.
NCT01707043 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT01707043 about?
NCT01707043 is a clinical study titled "Patient Preference of Taclonex Ointment to Taclonex Scalp Suspension in Adult Subjects With Psoriasis Vulgaris". This is an open label, investigator-blinded, cross over, prospective, single center study of subjects with plaque psoriasis. Taclonex® (calcipotriene 0.005% and betamethasone dipropionate 0.064%) Ointment and Taclonex Scalp® (calcipotriene 0.005% and betamethasone dipropionate 0.064%) Topical Suspen...
What is the current status of trial NCT01707043?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2012-10. Estimated completion is 2013-12.
What conditions does trial NCT01707043 study?
This clinical trial studies the following conditions: Plaque Psoriasis.
What interventions are being tested in trial NCT01707043?
The interventions under investigation include: Taclonex (DRUG).
Who is sponsoring clinical trial NCT01707043?
This trial is sponsored by Wake Forest University, which has 100 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01707043 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Plaque Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Guselkumab Immunogenetics
RECRUITING · Phase 4
-
Bimekizumab in Plaque Psoriasis
RECRUITING · Phase 4
-
Adrenal Suppression and Absorption Study of Halobetasol Propionate Foam in Subjects 12-17 With Plaque Psoriasis
COMPLETED · Phase 4
-
Patient Satisfaction Following Twice Daily Dosing With DFD-01 in Subjects With Moderate Plaque Psoriasis
COMPLETED · Phase 4
-
Subject Reported Target-lesion Numeric Rating Scale Evaluation by Subjects With Plaque Psoriasis Treated With Clobex® (Clobetasol Propionate) Spray 0.05%
COMPLETED · Phase 4
-
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.